Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Relacorilant

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corcept Shares ROSELLA Trial Data in Ovarian Cancer at ESMO
    Corcept Shares ROSELLA Trial Data in Ovarian Cancer at ESMO

    22 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250922541539/en/Corcept-to-Present-New-Late-Breaking-Data-From-Pivotal-ROSELLA-Trial-of-Relacorilant-in-Platinum-Resistant-Ovarian-Cancer-at-ESMO-2025

    BUSINESSWIRE
    22 Sep 2025
    Share Share
    FDA Files Corcept’s Relacorilant for Platinum-Resistant Ovarian
    FDA Files Corcept’s Relacorilant for Platinum-Resistant Ovarian

    10 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250910770269/en/FDA-Files-Corcepts-New-Drug-Application-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    10 Sep 2025
    Share Share
    Corcept Submits NDA for Ovarian Cancer Drug Relacorilant
    Corcept Submits NDA for Ovarian Cancer Drug Relacorilant

    14 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250714921466/en/Corcept-Submits-New-Drug-Application-for-Relacorilant-as-a-Treatment-for-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    14 Jul 2025
    Share Share
    Corcept Shows Relacorilant Improves Survival In Ovarian Cancer
    Corcept Shows Relacorilant Improves Survival In Ovarian Cancer

    02 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250602291571/en/Corcept-Presents-Pivotal-Clinical-Data-in-ASCO-Late-Breaker-with-Simultaneous-Publication-in-The-Lancet-Relacorilant-Improves-Progression-Free-and-Overall-Survival-in-Patients-with-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    02 Jun 2025
    Share Share
    Corcept to present late-breaking data from Rosella trial at ASCO Meeting
    Corcept to present late-breaking data from Rosella trial at ASCO Meeting

    23 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250422468615/en/CORCEPT-TO-PRESENT-LATE-BREAKING-DATA-FROM-PIVOTAL-PHASE-3-ROSELLA-TRIAL-OF-RELACORILANT-IN-PLATINUM-RESISTANT-OVARIAN-CANCER-AT-ASCO-2025

    BUSINESSWIRE
    23 Apr 2025
    Share Share
    Corcept Starts Trial in Platinum-Resistant Ovarian Cancer
    Corcept Starts Trial in Platinum-Resistant Ovarian Cancer

    07 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250407805321/en/Corcept-Initiates-Trial-of-Relacorilant-Plus-Nab-Paclitaxel-and-Bevacizumab-in-Patients-With-Platinum-Resistant-Ovarian-Cancer

    BUSINESSWIRE
    07 Apr 2025
    Share Share